Key points from article :
A new player has entered the booming longevity industry. Generation Lab, a startup offering personalized epigenetic testing, has raised $11 million in seed funding—marking Accel’s first-ever investment in the longevity space, as reported by Fortune. The round also saw participation from Samsung Next and celebrity investors such as Steve Aoki, Giannis Antetokounmpo, and Simu Liu, bringing the company’s total funding to $15 million.
Founded in 2023 by Alina Su, Dr. Irina Conboy of UC Berkeley (a leading figure in regenerative biology), and Michael Suswal (cofounder of Standard AI), Generation Lab’s mission is clear: to extend not just lifespan, but healthspan. As Su puts it, the aim is to add “20 extra healthy years” where people can remain active and independent—not to live forever, but to live better.
Generation Lab’s main product, the SystemAge report, begins with a blood test that measures 460 biomarkers across 19 organs and systems. The results provide a snapshot of how quickly different parts of the body are aging, helping users detect early health risks. The $490 test is already available in over 300 clinics across 18 countries, including the practice of Kim Kardashian’s physician.
Dr. Conboy emphasizes that aging isn’t a simple, linear process—rather, it fluctuates much like the pace of time itself. The company envisions a future where such personalized biological monitoring could not only guide individuals toward healthier aging but also detect large-scale public health issues before they emerge. As Accel’s Kerry Wang notes, longevity could soon become one of the defining markets of this generation—one that demands both innovation and credibility.
